XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma

(2016) Fabrice Jardin et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia

(2016) Preetesh Jain et al.   AMERICAN JOURNAL OF HEMATOLOGY

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone

(2016) Irfana Muqbil et al.   CANCER LETTERS

A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K

(2016) Iraia García-Santisteban et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

(2016) Ying Chen et al.   CLINICAL CANCER RESEARCH

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II  to the Nucleus

(2016) P. Ranganathan et al.   CLINICAL CANCER RESEARCH

Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma

(2016) V. Camus et al.   HAEMATOLOGICA

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

(2016) Mrinal M. Gounder et al.   JOURNAL OF CLINICAL ONCOLOGY

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

(2016) Xuejiao Liu et al.   Journal of Hematology & Oncology

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies

(2016) Z A Hing et al.   LEUKEMIA

Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma

(2016) Vincent Camus et al.   LEUKEMIA & LYMPHOMA

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

(2016) Jimi Kim et al.   NATURE

Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma

(2016) V. Camus et al.   HAEMATOLOGICA

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

(2015) Z. A. Hing et al.   BLOOD

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia

(2015) P. Ranganathan et al.   BLOOD

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

(2015) D. M. Kurtz et al.   BLOOD

Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing

(2015) Jasper E. Neggers et al.   CHEMISTRY & BIOLOGY

XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer

(2015) I. Ferreiro-Neira et al.   CLINICAL CANCER RESEARCH

Nuclear transport factors: global regulation of mitosis

(2015) Douglass J Forbes et al.   CURRENT OPINION IN CELL BIOLOGY

Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis

(2015) E. Bohers et al.   HAEMATOLOGICA

Identification of a Nuclear Export Sequence in the MHC CIITA

(2015) Emily Chiu et al.   JOURNAL OF IMMUNOLOGY

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study

(2015) Mark Roschewski et al.   LANCET ONCOLOGY

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

(2015) J Etchin et al.   LEUKEMIA

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer

(2015) S. Kazim et al.   MOLECULAR CANCER THERAPEUTICS

Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein

(2015) Jo Ishizawa et al.   PHARMACOLOGY & THERAPEUTICS

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185

(2015) Yoko Tabe et al.   PLoS One

Structural and Functional Characterization of CRM1-Nup214 Interactions Reveals Multiple FG-Binding Sites Involved in Nuclear Export

(2015) Sarah A. Port et al.   Cell Reports

Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis

(2015) E. Bohers et al.   HAEMATOLOGICA

RNA Export through the NPC in Eukaryotes

(2015) Masumi Okamura et al.   Genes

Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma

(2015) Matthew R Farren et al.   Journal for ImmunoTherapy of Cancer

Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL

(2014) J. Bond et al.   BLOOD

Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

(2014) Kieron Dunleavy et al.   BLOOD

Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells

(2014) J. Reichel et al.   BLOOD

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma

(2014) Mariko Yoshimura et al.   CANCER SCIENCE

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo

(2014) Y. Hao et al.   CLINICAL CANCER RESEARCH

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents

(2014) Kaushal Parikh et al.   Journal of Hematology & Oncology

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells

(2014) Y Zhong et al.   LEUKEMIA

Genomic and molecular characterization of esophageal squamous cell carcinoma

(2014) De-Chen Lin et al.   NATURE GENETICS

Nucleoporins and nucleocytoplasmic transport in hematologic malignancies

(2014) Akiko Takeda et al.   SEMINARS IN CANCER BIOLOGY

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia

(2013) Julia Etchin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention

(2013) Irfana Muqbil et al.   CURRENT DRUG TARGETS

Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas

(2013) A. S. Azmi et al.   HAEMATOLOGICA

Use of Statins and the Risk of Death in Patients With Prostate Cancer

(2013) Oriana Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

(2013) J Schmidt et al.   LEUKEMIA

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

(2013) B A Walker et al.   LEUKEMIA

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients

(2013) S Jeromin et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

Structural basis for cooperativity of CRM1 export complex formation

(2013) T. Monecke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1

(2013) Qingxiang Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CRM1 and its ribosome export adaptor NMD3 localize to the nucleolus and affect rRNA synthesis

(2013) Baoyan Bai et al.   Nucleus

FOXO1 is a tumor suppressor in classical Hodgkin lymphoma

(2012) L. Xie et al.   BLOOD

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma

(2012) Kejie Zhang et al.   EXPERIMENTAL HEMATOLOGY

A 2.1-Å-Resolution Crystal Structure of Unliganded CRM1 Reveals the Mechanism of Autoinhibition

(2012) Natsumi Saito et al.   JOURNAL OF MOLECULAR BIOLOGY

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

(2012) J Etchin et al.   LEUKEMIA

Sequence and structural analyses of nuclear export signals in the NESdb database

(2012) Darui Xu et al.   MOLECULAR BIOLOGY OF THE CELL

NESdb: a database of NES-containing CRM1 cargoes

(2012) Darui Xu et al.   MOLECULAR BIOLOGY OF THE CELL

Importin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal Biogenesis

(2012) Lior Golomb et al.   MOLECULAR CELL

Gray Zone Lymphoma: Better Treated Like Hodgkin Lymphoma or Mediastinal Large B-Cell Lymphoma?

(2012) Kieron Dunleavy et al.   Current Hematologic Malignancy Reports

Electrostatic Interactions Involving the Extreme C Terminus of Nuclear Export Factor CRM1 Modulate Its Affinity for Cargo

(2011) Abigail M. Fox et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1

(2010) Masako Koyama et al.   EMBO JOURNAL

NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1

(2010) Thomas Güttler et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A fraction of Crm1 locates at centrosomes by its CRIME domain and regulates the centrosomal localization of pericentrin

(2009) Qinying Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Structural basis for leucine-rich nuclear export signal recognition by CRM1

(2009) Xiuhua Dong et al.   NATURE

Structural basis for assembly and disassembly of the CRM1 nuclear export complex

(2009) Xiuhua Dong et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Crystal Structure of the Nuclear Export Receptor CRM1 in Complex with Snurportin1 and RanGTP

(2009) T. Monecke et al.   SCIENCE

Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure–activity relationship and mechanism of action

(2008) Tine Van Neck et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

(2008) Aurelia Noske et al.   CANCER

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

(2008) G. Lenz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA